메뉴 건너뛰기




Volumn 237, Issue 2, 2014, Pages 829-837

Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis

Author keywords

Cholesterol; Ezetimibe; Hypercholesterolemia; LDL C; Lipids; Lipoprotein; Statin

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; CERIVASTATIN; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

EID: 84911380386     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.10.105     Document Type: Article
Times cited : (39)

References (45)
  • 1
    • 78449281377 scopus 로고    scopus 로고
    • Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials
    • Baigent C., Blackwell L., Emberson J., Holland L.E., Reith C., Bhala N., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681.
    • (2010) Lancet , vol.376 , pp. 1670-1681
    • Baigent, C.1    Blackwell, L.2    Emberson, J.3    Holland, L.E.4    Reith, C.5    Bhala, N.6
  • 2
    • 84862119222 scopus 로고    scopus 로고
    • European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts)
    • * Developed with the special contribution of the European Association for Cardiovascular
    • Perk J., De Backer G., Gohlke H., Graham I., Reiner Z., Verschuren M., et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur. Heart J. 2012, 33:1635-1701.
    • (2012) Eur. Heart J. , vol.33 , pp. 1635-1701
    • Perk, J.1    De Backer, G.2    Gohlke, H.3    Graham, I.4    Reiner, Z.5    Verschuren, M.6
  • 3
    • 84893935789 scopus 로고    scopus 로고
    • An International Atherosclerosis Society position paper: global recommendations for the management of dyslipidemia - full report
    • Grundy S.M., Arai H., Barter P., Berso T.P., Betteridge D.J., Carmena R., et al. An International Atherosclerosis Society position paper: global recommendations for the management of dyslipidemia - full report. J.Clin. Lipidol. 2014, 8:29-60.
    • (2014) J.Clin. Lipidol. , vol.8 , pp. 29-60
    • Grundy, S.M.1    Arai, H.2    Barter, P.3    Berso, T.P.4    Betteridge, D.J.5    Carmena, R.6
  • 4
    • 84872712625 scopus 로고    scopus 로고
    • 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult
    • Anderson T.J., Grégoire J., Hegele R.A., Couture P., Mancini G.B., McPherson R., et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can. J. Cardiol. 2013, 29:151-167.
    • (2013) Can. J. Cardiol. , vol.29 , pp. 151-167
    • Anderson, T.J.1    Grégoire, J.2    Hegele, R.A.3    Couture, P.4    Mancini, G.B.5    McPherson, R.6
  • 5
    • 67651111687 scopus 로고    scopus 로고
    • Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals
    • Waters D.D., Brotons C., Chiang C.W., Ferrieres J., Foody J., Jukema J.W., et al. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation 2009, 120:28-34.
    • (2009) Circulation , vol.120 , pp. 28-34
    • Waters, D.D.1    Brotons, C.2    Chiang, C.W.3    Ferrieres, J.4    Foody, J.5    Jukema, J.W.6
  • 6
    • 61849116330 scopus 로고    scopus 로고
    • Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries
    • Kotseva K., Wood D., De Backer G., De Bacquer D., Pyorala K., Keil U. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009, 373:929-940.
    • (2009) Lancet , vol.373 , pp. 929-940
    • Kotseva, K.1    Wood, D.2    De Backer, G.3    De Bacquer, D.4    Pyorala, K.5    Keil, U.6
  • 7
    • 84897970506 scopus 로고    scopus 로고
    • 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
    • Stone N.J., Robinson J.G., Lichtenstein A.H., Bairey Merz C.N., Blum C.B., Eckel R.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2013, 129(25 Suppl.2):S1-S45.
    • (2013) Circulation , vol.129 , Issue.25 SUPPL.2 , pp. S1-S45
    • Stone, N.J.1    Robinson, J.G.2    Lichtenstein, A.H.3    Bairey Merz, C.N.4    Blum, C.B.5    Eckel, R.H.6
  • 8
    • 0030972796 scopus 로고    scopus 로고
    • The rule of 5 and the rule of 7 in lipid-lowering by statin drugs
    • Roberts W. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am. J. Cardiol. 1997, 80:106-107.
    • (1997) Am. J. Cardiol. , vol.80 , pp. 106-107
    • Roberts, W.1
  • 9
    • 72049130254 scopus 로고    scopus 로고
    • Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER)
    • Nicholls S.J., Brandrup-Wognsen G., Palmer M., Barter P.J. Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am. J. Cardiol. 2010, 105:69-76.
    • (2010) Am. J. Cardiol. , vol.105 , pp. 69-76
    • Nicholls, S.J.1    Brandrup-Wognsen, G.2    Palmer, M.3    Barter, P.J.4
  • 10
  • 11
    • 35748962429 scopus 로고    scopus 로고
    • The safety of statins in clinical practice
    • Armitage J. The safety of statins in clinical practice. Lancet 2007, 370:1781-1790.
    • (2007) Lancet , vol.370 , pp. 1781-1790
    • Armitage, J.1
  • 12
    • 84864915536 scopus 로고    scopus 로고
    • Use of lipid-lowering medications and the likelihood of achieving optimal LDL-cholesterol goals in coronary artery disease patients
    • Karalis D.G., Victor B., Ahedor L., Liu L. Use of lipid-lowering medications and the likelihood of achieving optimal LDL-cholesterol goals in coronary artery disease patients. Cholesterol 2012, 861924.
    • (2012) Cholesterol , pp. 861924
    • Karalis, D.G.1    Victor, B.2    Ahedor, L.3    Liu, L.4
  • 13
    • 77649195191 scopus 로고    scopus 로고
    • Therapy modifications and low-density lipoprotein cholesterol goal attainment rates associated with the initiation of generic simvastatin
    • Willey V.J., Bullano M.F., Shoetan N.N., Gandhi S.K. Therapy modifications and low-density lipoprotein cholesterol goal attainment rates associated with the initiation of generic simvastatin. Curr. Med. Res. Opin. 2010, 26:121-128.
    • (2010) Curr. Med. Res. Opin. , vol.26 , pp. 121-128
    • Willey, V.J.1    Bullano, M.F.2    Shoetan, N.N.3    Gandhi, S.K.4
  • 14
    • 77950346846 scopus 로고    scopus 로고
    • LDL-C goal attainment in patients who remain on atorvastatin or switch to equivalent or non-equivalent doses of simvastatin: a retrospective matched cohort study in clinical practice
    • Rublee D.A., Burke J.P. LDL-C goal attainment in patients who remain on atorvastatin or switch to equivalent or non-equivalent doses of simvastatin: a retrospective matched cohort study in clinical practice. Postgrad. Med. 2010, 122:16-24.
    • (2010) Postgrad. Med. , vol.122 , pp. 16-24
    • Rublee, D.A.1    Burke, J.P.2
  • 15
    • 84855171302 scopus 로고    scopus 로고
    • Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy
    • The AIM-HIGH Investigators Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N.Engl. J. Med. 2011, 365:2255-2267.
    • (2011) N.Engl. J. Med. , vol.365 , pp. 2255-2267
  • 16
    • 84877299845 scopus 로고    scopus 로고
    • HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment
    • HPS2-THRIVE Collaborative Group HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur. Heart J. 2013, 34:1279-1291.
    • (2013) Eur. Heart J. , vol.34 , pp. 1279-1291
  • 17
    • 77951704587 scopus 로고    scopus 로고
    • Effects of combination lipid therapy in type 2 diabetes mellitus
    • ACCORD Study Group Effects of combination lipid therapy in type 2 diabetes mellitus. N.Engl. J. Med. 2010, 362:1563-1574.
    • (2010) N.Engl. J. Med. , vol.362 , pp. 1563-1574
  • 18
    • 84905040766 scopus 로고    scopus 로고
    • Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population
    • Blazing M.A., Giugliano R.P., Cannon C.P., Musliner T.A., Tershakovec A.M., White J.A., et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population. Am. Heart J. 2014, 168:205-212.
    • (2014) Am. Heart J. , vol.168 , pp. 205-212
    • Blazing, M.A.1    Giugliano, R.P.2    Cannon, C.P.3    Musliner, T.A.4    Tershakovec, A.M.5    White, J.A.6
  • 19
    • 78149457142 scopus 로고    scopus 로고
    • Update on the efficacy and safety of combination ezetimibe plus statin therapy
    • Toth P.P., Catapano A., Tomassini J.E., Tershakovec A.M. Update on the efficacy and safety of combination ezetimibe plus statin therapy. Clin. Lipidol. 2010, 5:655-684.
    • (2010) Clin. Lipidol. , vol.5 , pp. 655-684
    • Toth, P.P.1    Catapano, A.2    Tomassini, J.E.3    Tershakovec, A.M.4
  • 20
    • 84889813405 scopus 로고    scopus 로고
    • Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy
    • Foody J.M., Toth P.P., Tomassini J.E., Sajjan S., Ramey D.R., Neff D., et al. Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy. Vasc. Health Risk Manag. 2013, 9:719-727.
    • (2013) Vasc. Health Risk Manag. , vol.9 , pp. 719-727
    • Foody, J.M.1    Toth, P.P.2    Tomassini, J.E.3    Sajjan, S.4    Ramey, D.R.5    Neff, D.6
  • 21
    • 84856358934 scopus 로고    scopus 로고
    • Ezetimibe/simvastatin 10/40 mg versus atorvastatin 40 mg in high cardiovascular risk patients with primary hypercholesterolemia: a randomized, double-blind, active-controlled, multicenter study
    • Hing Ling P.K., Civeira F., Dan A.G., Hanson M.E., Massaad R., De Tilleghem Cle B., et al. Ezetimibe/simvastatin 10/40 mg versus atorvastatin 40 mg in high cardiovascular risk patients with primary hypercholesterolemia: a randomized, double-blind, active-controlled, multicenter study. Lipids Health Dis. 2012, 11:18.
    • (2012) Lipids Health Dis. , vol.11 , pp. 18
    • Hing Ling, P.K.1    Civeira, F.2    Dan, A.G.3    Hanson, M.E.4    Massaad, R.5    De Tilleghem Cle, B.6
  • 22
    • 62549118503 scopus 로고    scopus 로고
    • Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - the IN-CROSS study
    • Farnier M., Averna M., Missault L., Vaverkova H., Viigimaa M., Massaad R., et al. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - the IN-CROSS study. Int. J. Clin. Pract. 2009, 63:547-559.
    • (2009) Int. J. Clin. Pract. , vol.63 , pp. 547-559
    • Farnier, M.1    Averna, M.2    Missault, L.3    Vaverkova, H.4    Viigimaa, M.5    Massaad, R.6
  • 23
    • 79960901604 scopus 로고    scopus 로고
    • Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study)
    • Bays H.E., Davidson M.H., Massaad R., Flaim D., Lowe R.S., Tershakovec A.M., et al. Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study). Am. J. Cardiol. 2011, 108:523-530.
    • (2011) Am. J. Cardiol. , vol.108 , pp. 523-530
    • Bays, H.E.1    Davidson, M.H.2    Massaad, R.3    Flaim, D.4    Lowe, R.S.5    Tershakovec, A.M.6
  • 24
    • 76849095375 scopus 로고    scopus 로고
    • Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in patients > or= 65 years of age (from the ZETia in the ELDerly [ZETELD] study)
    • Zieve F., Wenger N.K., Ben Yehuda O., Constance C., Bird S., Lee R., et al. Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in patients > or= 65 years of age (from the ZETia in the ELDerly [ZETELD] study). Am. J. Cardiol. 2010, 106:656-663.
    • (2010) Am. J. Cardiol. , vol.106 , pp. 656-663
    • Zieve, F.1    Wenger, N.K.2    Ben Yehuda, O.3    Constance, C.4    Bird, S.5    Lee, R.6
  • 25
    • 84888585549 scopus 로고    scopus 로고
    • Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia
    • Bays H.E., Averna M., Majul C., Muller-Wieland D., De Pellegrin A., Giezek H., et al. Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia. Am. J. Cardiol. 2013, 112:1885-1895.
    • (2013) Am. J. Cardiol. , vol.112 , pp. 1885-1895
    • Bays, H.E.1    Averna, M.2    Majul, C.3    Muller-Wieland, D.4    De Pellegrin, A.5    Giezek, H.6
  • 26
    • 84864753387 scopus 로고    scopus 로고
    • Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials
    • Morrone D., Weintraub W.S., Toth P.P., Hanson M.E., Lowe R.S., Lin J., et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis 2012, 223:251-261. 10.1016/j.atherosclerosis.2012.02.016.
    • (2012) Atherosclerosis , vol.223 , pp. 251-261
    • Morrone, D.1    Weintraub, W.S.2    Toth, P.P.3    Hanson, M.E.4    Lowe, R.S.5    Lin, J.6
  • 27
    • 0037111890 scopus 로고    scopus 로고
    • Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia
    • Gagne C., Bays H.E., Weiss S.R., Mata P., Quinto K., Melino M., et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am. J. Cardiol. 2002, 90:1084-1091.
    • (2002) Am. J. Cardiol. , vol.90 , pp. 1084-1091
    • Gagne, C.1    Bays, H.E.2    Weiss, S.R.3    Mata, P.4    Quinto, K.5    Melino, M.6
  • 28
    • 18244390229 scopus 로고    scopus 로고
    • Acommunity-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial
    • Pearson T.A., Denke M.A., McBride P.E., Battisti W.P., Brady W.E., Palmisano J. Acommunity-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin. Proc. 2005, 80:587-595.
    • (2005) Mayo Clin. Proc. , vol.80 , pp. 587-595
    • Pearson, T.A.1    Denke, M.A.2    McBride, P.E.3    Battisti, W.P.4    Brady, W.E.5    Palmisano, J.6
  • 29
    • 18744376636 scopus 로고    scopus 로고
    • LDL-C goal attainment with the addition of ezetimibe to ongoing simvastatin treatment in coronary heart disease patients with hypercholesterolemia
    • Brohet C., Banai S., Alings A.M., Massaad R., Davies M.J., Allen C. LDL-C goal attainment with the addition of ezetimibe to ongoing simvastatin treatment in coronary heart disease patients with hypercholesterolemia. Curr. Med. Res. Opin. 2005, 21:571-578.
    • (2005) Curr. Med. Res. Opin. , vol.21 , pp. 571-578
    • Brohet, C.1    Banai, S.2    Alings, A.M.3    Massaad, R.4    Davies, M.J.5    Allen, C.6
  • 30
    • 20744455079 scopus 로고    scopus 로고
    • Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease
    • Farnier M., Volpe M., Massaad R., Davies M.J., Allen C. Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease. Int. J. Cardiol. 2005, 102:327-332.
    • (2005) Int. J. Cardiol. , vol.102 , pp. 327-332
    • Farnier, M.1    Volpe, M.2    Massaad, R.3    Davies, M.J.4    Allen, C.5
  • 31
    • 23844497814 scopus 로고    scopus 로고
    • Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease
    • Cruz-Fernandez J.M., Bedarida G.V., Adgey J., Allen C., Johnson-Levonas A.O., Massaad R. Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease. Int. J. Clin. Pract. 2005, 59:619-627.
    • (2005) Int. J. Clin. Pract. , vol.59 , pp. 619-627
    • Cruz-Fernandez, J.M.1    Bedarida, G.V.2    Adgey, J.3    Allen, C.4    Johnson-Levonas, A.O.5    Massaad, R.6
  • 33
    • 4644256971 scopus 로고    scopus 로고
    • Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin
    • Stein E., Stender S., Mata P., Sager P., Ponsonnet D., Melani L., et al. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am. Heart J. 2004, 148:447-455.
    • (2004) Am. Heart J. , vol.148 , pp. 447-455
    • Stein, E.1    Stender, S.2    Mata, P.3    Sager, P.4    Ponsonnet, D.5    Melani, L.6
  • 34
    • 12744274866 scopus 로고    scopus 로고
    • Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients
    • Gaudiani L.M., Lewin A., Meneghini L., Perevozskaya I., Plotkin D., Mitchel Y., et al. Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients. Diabetes Obes. Metab. 2005, 7:88-97.
    • (2005) Diabetes Obes. Metab. , vol.7 , pp. 88-97
    • Gaudiani, L.M.1    Lewin, A.2    Meneghini, L.3    Perevozskaya, I.4    Plotkin, D.5    Mitchel, Y.6
  • 35
    • 58149473593 scopus 로고    scopus 로고
    • Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus up-titration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease
    • Conard S.E., Bays H.E., Leiter L.A., Bird S.R., Rubino J., Lowe R.S., et al. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus up-titration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease. Am. J. Cardiol. 2008, 102:1489-1494.
    • (2008) Am. J. Cardiol. , vol.102 , pp. 1489-1494
    • Conard, S.E.1    Bays, H.E.2    Leiter, L.A.3    Bird, S.R.4    Rubino, J.5    Lowe, R.S.6
  • 36
    • 58149472552 scopus 로고    scopus 로고
    • Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with up-titration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease
    • Leiter L.A., Bays H., Conard S., Bird S., Rubino J., Hanson M.E., et al. Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with up-titration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease. Am. J. Cardiol. 2008, 102:1495-1501.
    • (2008) Am. J. Cardiol. , vol.102 , pp. 1495-1501
    • Leiter, L.A.1    Bays, H.2    Conard, S.3    Bird, S.4    Rubino, J.5    Hanson, M.E.6
  • 37
    • 33645235185 scopus 로고    scopus 로고
    • Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease
    • Barrios V., Amabile N., Paganelli F., Chen J.W., Allen C., Johnson-Levonas A.O., et al. Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease. Int. J. Clin. Pract. 2005, 59:1377-1386.
    • (2005) Int. J. Clin. Pract. , vol.59 , pp. 1377-1386
    • Barrios, V.1    Amabile, N.2    Paganelli, F.3    Chen, J.W.4    Allen, C.5    Johnson-Levonas, A.O.6
  • 38
    • 34347399601 scopus 로고    scopus 로고
    • Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus
    • Constance C., Westphal S., Chung N., Lund M., McCrary Sisk C., Johnson-Levonas A.O., et al. Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 2007, 9:575-584.
    • (2007) Diabetes Obes. Metab. , vol.9 , pp. 575-584
    • Constance, C.1    Westphal, S.2    Chung, N.3    Lund, M.4    McCrary Sisk, C.5    Johnson-Levonas, A.O.6
  • 39
    • 84873435386 scopus 로고    scopus 로고
    • Acomparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid-lowering treatment strategies in diabetic patients with symptomatic cardiovascular disease
    • Rosen J.B., Jimenez J.B., Pirags V., Vides H., Hanson M.E., Massaad R., et al. Acomparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid-lowering treatment strategies in diabetic patients with symptomatic cardiovascular disease. Diabetes Vasc. Dis. Res. 2013, 10:277-286.
    • (2013) Diabetes Vasc. Dis. Res. , vol.10 , pp. 277-286
    • Rosen, J.B.1    Jimenez, J.B.2    Pirags, V.3    Vides, H.4    Hanson, M.E.5    Massaad, R.6
  • 40
    • 51549108029 scopus 로고    scopus 로고
    • Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation
    • Ara R., Tumur I., Pandor A., Duenas A., Williams R., Wilkinson A., et al. Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation. Health Technol. Assess. 2008, 12:21.
    • (2008) Health Technol. Assess. , vol.12 , pp. 21
    • Ara, R.1    Tumur, I.2    Pandor, A.3    Duenas, A.4    Williams, R.5    Wilkinson, A.6
  • 41
    • 84893937252 scopus 로고    scopus 로고
    • Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease
    • Toth P.P., Foody J.M., Tomassini J.E., Sajjan S.G., Ramey D.R., Neff D.R., et al. Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease. J.Clin. Lipidol. 2014, 8:107-116.
    • (2014) J.Clin. Lipidol. , vol.8 , pp. 107-116
    • Toth, P.P.1    Foody, J.M.2    Tomassini, J.E.3    Sajjan, S.G.4    Ramey, D.R.5    Neff, D.R.6
  • 42
    • 84884341099 scopus 로고    scopus 로고
    • Efficacy of combination of ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes
    • Torimoto K., Okada Y., Mori H., Hajime M., Tanaka K., Kurozumi A., et al. Efficacy of combination of ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes. Lipids Health Dis. 2013, 12:137.
    • (2013) Lipids Health Dis. , vol.12 , pp. 137
    • Torimoto, K.1    Okada, Y.2    Mori, H.3    Hajime, M.4    Tanaka, K.5    Kurozumi, A.6
  • 44
    • 37849034077 scopus 로고    scopus 로고
    • Understanding practice patterns and low-density lipoprotein cholesterol goal attainment implications of switching patients from simvastatin in a health plan setting
    • Harley C.R., Gandhi S.K., Anoka N., Bullano M.F., McKenney J.M. Understanding practice patterns and low-density lipoprotein cholesterol goal attainment implications of switching patients from simvastatin in a health plan setting. Am. J. Manag. Care 2007, 13:S276-S281.
    • (2007) Am. J. Manag. Care , vol.13 , pp. S276-S281
    • Harley, C.R.1    Gandhi, S.K.2    Anoka, N.3    Bullano, M.F.4    McKenney, J.M.5
  • 45
    • 0037126729 scopus 로고    scopus 로고
    • Evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report
    • National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421.
    • (2002) Circulation , vol.106 , pp. 3143-3421


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.